Syntopix signs evaluation agreement with consumer healthcare company

Syntopix Group, a speciality pharmaceutical research and development company in the UK focused on topical treatment of dermatological diseases, has signed an exclusive evaluation agreement with a major consumer healthcare company.

Under the terms of the agreement, Bradford-based Syntopix will make available its library of compounds for evaluation of their application in a number of areas as candidates for development into commercial products.

The financial details of the agreement remain confidential, although Syntopix will receive an upfront payment at the start of the exclusivity period and further payments for any compounds subject to additional evaluation. Commercialisation of a compound would be subject to a licence agreement to be negotiated separately.

This agreement highlights the company's strategy of leveraging its compound library and intellectual property into consumer healthcare markets.

Dr Stephen Jones, chief executive of Syntopix, said: "I am delighted that Syntopix has entered into this agreement with one of the world's largest consumer healthcare companies. We continue to identify potential markets for the antimicrobial expertise of Syntopix, and we believe that our technology has the potential to improve the effectiveness of many healthcare brands."

Syntopix is based at the Institute of Pharmaceutical Innovation in Bradford, which gives it access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds.